XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
XTL Biopharmaceuticals Ltd. has announced its strategic acquisition of The Social Proxy Ltd., a web data AI company specializing in AI and BI applications, which will become a fully owned subsidiary and contribute to XTL’s asset portfolio expansion. The acquisition is supported by a $1.5 million private placement investment and includes an agreement for Social Proxy shareholders to appoint two board members to XTL’s board. This move aligns with XTL’s ongoing efforts to identify and integrate high-potential IP-based assets into its portfolio.
For further insights into XTLB stock, check out TipRanks’ Stock Analysis page.